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Abstract
Introduction: Comorbidities including diabetes mellitus (DM) among people living with HIV (PLHIV) are of increasing clinical
concerns in combination antiretroviral therapy (cART) era. We aimed to determine the incidence and risk factors of new-onset
DM among PLHIV in Asian settings.
Methods: PLHIV from a regional observational cohort without DM prior to antiretroviral therapy (ART) initiation were
included in the analysis. DM was defined as having a fasting blood glucose ≥126 mg/dL, glycated haemoglobin ≥6.5%, a two-
hour plasma glucose ≥200 mg/dL, or a random plasma glucose ≥200 mg/dL. A Cox regression model, stratified by site, was
used to identify risk factors associated with DM.
Results and discussion: Of the 1927 participants included, 127 were diagnosed with DM after ART initiation. Median follow-
up time from ART initiation to DM diagnosis was 5.9 years (interquartile range (IQR): 2.8 to 8.9 years). The crude incidence
rate of DM was 1.08 per 100 person-years (100 PYS), 95% confidence interval (CI) (0.9 to 1.3). In the multivariate analysis,
later years of follow-up (2011 to 2013: HR = 2.34, 95% CI 1.14 to 4.79, p = 0.02; and 2014 to 2017: HR = 7.20, 95% CI
3.27 to 15.87, p < 0.001) compared to <2010, older age (41 to 50 years: HR = 2.46, 95% CI 1.39 to 4.36, p = 0.002; and
>50 years: HR = 4.19, 95% CI 2.12 to 8.28, p < 0.001) compared to <30 years, body mass index (BMI) >30 kg/m2 (HR = 4.3,
95% CI 1.53 to 12.09, p = 0.006) compared to BMI <18.5 kg/m2, and high blood pressure (HR = 2.05, 95% CI 1.16 to 3.63,
p = 0.013) compared to those without high blood pressure, were associated with developing DM. The hazard was reduced for
females (HR = 0.47, 95% CI 0.28 to 0.80, p = 0.006).
Conclusions: Type 2 DM in HIV-infected Asians was associated with later years of follow-up, high blood pressure, obesity and
older age. This highlights the importance of monitoring and routine screening for non-communicable diseases including DM as
PLHIV age.
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1 | INTRODUCTION
People living with human immunodeficiency virus (PLHIV)
have better prognosis and greater longevity because of the
benefits of highly effective combination antiretroviral therapy
(cART), more effective management strategies and improve-
ments in patient monitoring [1-5]. With increasing survival,
non-AIDS complications and comorbidities are important key
factors influencing morbidity and mortality among PLHIV.
Studies have pointed out metabolic disorders such as diabetes
mellitus (DM) were common in PLHIV [6,7]. A study using
nationally representative survey data from the U.S. showed
that DM prevalence was 3.8% higher in HIV-infected individu-
als compared with the uninfected general population [6]. A
report from the Data Collection on Adverse Events of Anti-
HIV Drugs (D:A:D) study showed that the incidence of DM
was 5.7 per 1000 person-years of follow-up [8].
Use of certain protease inhibitors (PI)-based regimen has
been reported [9] to be associated with higher incidence of
DM in the early antiretroviral therapy (ART) era, but the asso-
ciations were less common with the newer classes of PI.
Antiretrovirals (ARV) containing older classes of nucleoside
reverse transcriptase inhibitors (NRTIs) such as stavudine or
didanosine might also increase the risk of developing DM,
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probably due to insulin resistance caused by mitochondrial
toxicities [10-12]. Moreover, DM is commonly associated with
other comorbidities such as hypertension and dyslipidaemia,
which can result in increased risk of developing cardiovascular
diseases [10,13].
Non-communicable diseases including DM have been
increased dramatically over the past few decades in Asia [14],
of which more than half of the global DM population are
located in this region [15]. However, DM prevalence data
among PLHIV in Asia-Pacific region is still sparse. The inci-
dence of DM varied among HIV population (0.5 to 1.31 cases
per 100 persons-years of follow-up) in HIV population
[8,10,16]. The incidence of DM in Asia varied from Western
countries and the risk factors for the development of DM
among PLHIV are understudied in the region. Hence, we
assessed the incidence and risk factors of new-onset DM
among PLHIV after cART initiation in a regional observational
cohort in the Asia-Pacific region.
2 | METHODS
2.1 | Study design and participants
This study was a longitudinal analysis exploring the incidence
of new-onset DM after cART initiation. The study participants
were PLHIV enrolled in the TREAT Asia HIV Observational
Database (TAHOD) between 2003 and 2017. The cohort
and its methods have previously been characterized [17-19].
The TAHOD is a collaborative observational cohort study
that involves 20 sites in the Asia and Pacific region. The par-
ticipating countries are Cambodia, China and Hong Kong
SAR, India, Indonesia, Japan, Malaysia, the Philippines, Singa-
pore, South Korea, Taiwan, Thailand and Vietnam. The recruit-
ment began in 2003. As of March 2017, there were 9160
participants enrolled. Data transfer occurs every six months
in March and September. TAHOD does not mandate regular
visit schedule and all tests/interventions are performed
according to the site’s local practices. Participants were
included in this analysis if they have been on cART for more
than six months, did not have evidence of DM prior to start
of cART, and had at least one of the following measurements
after cART initiation: fasting blood glucose (FBG), glycated
haemoglobin (HbA1C), two-hour plasma glucose after 75 g
oral glucose tolerance test (OGTT), or a random plasma glu-
cose (RPG). Participants without DM screening prior to cART
initiation were excluded from the study. Participant consent
was deferred according to the individual participating sites
and their institutional review boards, and is not required for
all participants.
2.2 | Outcomes
DM was defined as having a single measurement showing
FBG ≥126 mg/dL, HbA1C ≥6.5%, a two-hour plasma glucose
level after OGTT ≥200 mg/dL, or a RPG ≥200 mg/dL, modi-
fied from the standard criteria for DM diagnosis from Ameri-
can Diabetes Association [20]. However, we did not include
data of hyperglycaemic symptoms for RPG ≥200 mg/dL. Also,
we did not use secondary confirmation testing of FBG as our
median FBG testing frequency was once per patient per year
(interquartile range (IQR) 1 to 2).
2.3 | Covariates
Time-fixed covariates included age, sex, mode of HIV
exposure, initial cART regimen, any exposure to stavudine or
didanosine in their first-line ART regimen, hepatitis B and C
co-infection, prior AIDS diagnosis, smoking and alcohol status.
Time-updated covariates included calendar year of follow-up,
viral load, CD4, body mass index (BMI), high blood pressure
and dyslipidaemia. Dyslipidaemia was defined as a single labo-
ratory result of a fasting cholesterol >200 mg/dL or triglyc-
erides >150 mg/dL. High blood pressure was defined as
having at least one measurement of systolic blood pressure
>140 mmHg or diastolic blood pressure >90 mmHg. All vari-
ables were categorical in the regression analysis.
2.4 | Statistical analysis
Factors associated with DM diagnosis after cART initiation
were analysed using a Cox regression model stratified by site,
to account for clustering within each site. Risk time for DM
started from cART initiation and ended on date of first DM
diagnosis, among participants who have been on cART for at
least six months. Participants without DM events were cen-
sored on the date of last measurement for DM markers. Since
the study was an intention-to-treat analysis, we included cART
regimen and individual ART drugs as time-fixed covariates.
Pre-ART VL and CD4 cell count were defined as measure-
ments taken within six months prior to start of cART. Prior
AIDS diagnosis was defined as having a CDC disease stage C
prior to cART initiation. All variables measured were entirely
observational according to site’s local practices. Covariates
from the univariate analysis with p < 0.10 were fitted in the
multivariate model using backward stepwise selection process.
Covariates with p < 0.05 in the multivariate model were con-
sidered significant.
Ethics approval were obtained from respective local ethics
committees of all TAHOD-participating sites, the Kirby Insti-
tute (data management and statistical analysis centre), and
TREAT Asia/amfAR (coordinating centre). All data manage-
ment and statistical analyses were performed using SAS soft-
ware version 9.4 (SAS Institute Inc., Cary, NC, USA) and Stata
software version 14.2 (Stata Corp., College Station, TX, USA).
3 | RESULTS AND DISCUSSION
A total of 1927 PLHIV receiving cART with no evidence of
prior DM were included from 20 sites from the participating
countries in TAHOD cohort. Of participants with glucose
parameters available prior to cART initiation, there were 228
participants with previous diagnosis of DM who were
excluded from the study. Sites contributed a median of 61
participants (IQR 20 to 163 participants) in the analysis. The
median age was 35 years (IQR 30 to 41) and the median
CD4 cell count at ART initiation was 162 cells/lL (IQR: 59 to
248) (Table 1). The majority were males (74%) and acquired
HIV via heterosexual route (57%). Hepatitis C virus co-infec-
tion occurred in 11% of total PLHIV. 1497 (78%) and 364
(19%) of the participants were on NRTIs plus NNRTI (non-
nucleoside reverse transcriptase inhibitor) and NRTIs plus PI
as initial cART regimen respectively.
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Table 1. Patient characteristics
Total patients (%) Total DM
N = 1927 (100) N = 127 (7)
Median age at ART initiation (years) Median = 35, IQR (30 to 41) Median = 38, IQR (32 to 45)
Sex
Male 1426 (74) 109 (86)
Female 501 (26) 18 (14)
HIV mode of exposure
Heterosexual contact 1102 (57) 70 (55)
MSM 554 (29) 34 (27)
IDU 105 (5) 12 (9)
Other/Unknown 166 (9) 11 (9)
Pre-ART Viral Load (copies/mL) Median = 78,340, IQR (18,752 to 240,000) Median = 72,865, IQR (16,397 to 490,000)
Pre-ART CD4 (cells/lL) Median = 162, IQR (59 to 248) Median = 125, IQR (42 to 201)
Initial cART regimen
NRTI + NNRTI 1497 (78) 102 (80)
NRTI + PI 364 (19) 22 (17)
Other combination 66 (3) 3 (2)
Stavudine in first-line ART
No 1382 (72) 80 (63)
Yes 545 (28) 47 (37)
Didanosine in first-line ART
No 1879 (98) 120 (94)
Yes 48 (2) 7 (6)
Hepatitis B co-infection
Negative 1599 (83) 100 (79)
Positive 142 (7) 16 (13)
Not tested 186 (10) 11 (9)
Hepatitis C co-infection
Negative 1422 (74) 96 (76)
Positive 204 (11) 13 (10)
Not tested 301 (16) 18 (14)
Prior AIDS diagnosis
No 1367 (71) 79 (62)
Yes 560 (29) 48 (38)
Ever smoked
No 755 (39) 41 (32)
Yes 663 (34) 48 (38)
Not reported 509 (26) 38 (30)
Ever above moderate or low risk drinking
No 324 (17) 20 (16)
Yes 107 (6) 10 (8)
Not reported 1496 (78) 97 (76)
Pre-ART BMI (kg/m2) Median = 21, IQR (19 to 23) Median = 22, IQR (19 to 25)
Pre-ART systolic blood pressure (mmHg) Median = 112, IQR (100 to 123) Median = 110, IQR (100 to 120)
Pre-ART diastolic blood pressure (mmHg) Median = 70, IQR (63 to 80) Median = 70, IQR (60 to 80)
Pre-ART ALT (U/L) Median = 29, IQR (19 to 45) Median = 34, IQR (21 to 54)
Pre-ART fasting blood glucose (mmol/L) Median = 4.9, IQR (4.5 to 5.4) Median = 5.4, IQR (4.7 to 6.1)
Pre-ART random blood glucose (mmol/L) Median = 5.2, IQR (4.9 to 5.4) N/A
ART, antiretroviral therapy; BMI, body mass index; IDU, injecting drug users; IQR, interquartile range; MSM, men who have sex with men; NNRTI,
non-nucleoside reverse transcriptase inhibitor; NRTI, nucleoside reverse transcriptase inhibitors; PI, protease inhibitor.
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There were 127 PLHIV (7%) who had DM after cART with
an incidence rate of 1.08 per 100 person-years (/100PYS)
under a median follow-up time of 5.9 years (IQR: 2.8 to
8.9 years). Of the 127 participants, 117 met the FBG criteria,
9 met the HbA1C criteria and 1 met the OGTT criteria for
DM. The incidence rate for DM for those with HCV co-infec-
tion was 1.18/100PYS which was higher than 1.05/100PYS
for HCV negative participants, however the HR was not sta-
tistically significant when included in the univariate Cox
regression analysis (p = 0.219). Factors associated with devel-
opment of DM after ART initiation are shown in Table 2. Cal-
endar year of follow-up (p < 0.001), age (p < 0.001), sex
(p = 0.004), BMI (p = 0.009), high blood pressure (p = 0.001)
and dyslipidaemia (p = 0.059) were significant in the univari-
ate analysis and included in the multivariate model.
In the multivariate analysis, factors associated with DM
diagnosis included later years of follow-up (years 2011 to
2013: HR = 2.34, 95% confidence interval (CI) 1.14 to 4.79,
p = 0.02; and years 2014 to 2017: HR = 7.20, 95% CI 3.27
to 15.87, p < 0.001) compared to follow-up years before
2010; older age at cART initiation (41 to 50 years: HR = 2.46,
95% CI 1.39 to 4.36, p = 0.002; and >50 years: HR = 4.19,
95% CI 2.12 to 8.28, p < 0.001) compared to age <30 years;
having BMI >30 kg/m2 (HR = 4.3, 95% CI 1.53 to 12.09,
p = 0.006) compared to BMI <18.5 kg/m2; and having high
blood pressure (HR = 2.05, 95% CI 1.16 to 3.63, p = 0.013)
compared to those without high blood pressure. The female
sex was associated with 53% reduction in hazard for DM
(HR = 0.47, 95% CI 0.28 to 0.80, p = 0.006) compared to
males.
Overall incidence of new-onset DM is 1.08 per 100PYS in a
median follow-up time of nearly six years after cART initiation
among PLHIV from a cohort in the Asia-Pacific region. Risk
factors associated with new-onset DM in this cohort includes
older age, higher BMI and high blood pressure. The DM inci-
dence is similar to previous studies [10,16] in the Asia-Pacific
region, with a total of 11,798 person-years of follow-up
among 1927 PLHIV in our multicenter cohort in the Asia-Paci-
fic, which includes 20 sites from 12 different countries and
territories. The incidence rate of DM was higher among males
(1.22/100PYS) compared to females (0.63/100PYS). Tradi-
tional risks factors such as age, BMI and high blood pressure
were found to be predictors of DM, reflecting the emergence
of non-communicable disease comorbidities. In addition, we
also found that the later years of follow-up was associated
with higher DM incidence, compared to follow-up years
before 2010. This could be partly due to the collection of
OGTT, HbA1C and RPG results into the cohort after 2015,
although the routine FBG median FBG testing frequency was
the same as once per patient per year. We did not observe an
association between DM and the use of baseline ARVs such
as stavudine or didanosine in the initial regimen or the use of
PIs- or NNRTIs-based regimen as baseline ART.
Incident DM was more common in males, participants with
increasing age and higher BMI, which are consistent with the
risk factors among the general population. Moreover, there
was no significant difference between HIV exposure risks
(heterosexual, men who have sex with men (MSM) and
injectable drug users) and incident DM in our study. DM
incidence among PLHIV has varied by geographic region and
country income level. The US Multicenter AIDS Cohort Study
(MACS) [21] and Women’s Interagency HIV Study (WIHS)
[22], where the majority of the participants were African-
American and Hispanic/Latino, have reported higher inci-
dence rates of DM, with 4.7/100PYS and 3.4/100PYS among
HIV-infected participants on ART in MACS and WIHS
respectively. Our findings were similar to the incidence rates
from the previous studies [10,16,23]. However, lower rates
have been reported from other cohorts such as Swiss HIV
Cohort [24] and D:A:D study [8], with incidence rates of
0.44/100PYS and 0.57/100PYS respectively. Differences in
DM incidence rates among the cohorts are possibly due to
different ethnic backgrounds since Asians are more prone to
have more visceral adipose tissue accumulation than Euro-
pean population, which could lead to higher chances of insu-
lin resistance [25,26]. Additionally, the differences in DM
incidence among cohorts may also be contributed by the dif-
ferences in the length of follow-up time and the definition of
DM we used in the study which did not require a confirma-
tion test of fasting blood sugar which can result in having
lower specificity for detecting DM.
With regard to HIV- and ART-related factors, we did not
observe associations between DM and time-updated CD4 cell
counts, HIV viral load or prior AIDS-defining events. Previous
reports have suggested that persistent inflammation due to
chronic infection may have an impact on the pathogenesis of
DM [27]. In addition to the effect of chronic inflammation of
HIV infection on insulin resistance, past studies have shown
an association of ART with DM development. Most of our par-
ticipants (80%) who developed DM were on NNRTIs-based
regimen as initial cART. In this analysis, we did not find the
link of either stavudine or didanosine with incident DM, even
though the use of stavudine as initial cART regimen was high
(28%) in our cohort. It is interesting to note that stavudine
was suggested to have been associated with lipodystrophy
[28] but not DM in the same population. Furthermore, certain
PIs may contribute to the inhibition of glucose transporter
(glucose transporter type 4 isoform, GLUT4) and the reduc-
tion in insulin sensitivity, which could lead to decreased glu-
cose uptake in peripheral adipose tissues and consequently
result in the development of insulin resistance [29]. Contrary
to the previous studies [9,24], we found no association
between DM and PI- versus NNRTI-based initial cART
regimen.
It is noteworthy that high blood pressure was also associ-
ated with DM incidence in our cohort. This is consistent with
the findings from the general population without HIV infec-
tion [30]. HIV-infected participants with high blood pressure
and DM may also have risks for multiple comorbidities and
polypharmacy. This will increase the pill burden and have a
high possibility to have drug-to-drug interactions. Therefore,
proper treatment and risk reduction strategies such as diet
and exercise should be implemented in those who have
higher BMI and abnormal blood pressure. Our findings
showed that traditional risk factors were associated with
DM development among Asian HIV-infected individuals, sug-
gesting the needs for the importance of clinicians to timely
diagnose and properly manage DM in HIV-infected individu-
als. Even though we did not observe the use of ARVs to be
an additional risk for the occurrence of DM, however it
remains crucial to monitor and evaluate the potential toxici-
ties from different ARVs used.
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(years) No of DM
Incidence rate
(/100PYS) HR (95% CI) p-value HR (95% CI) p-value
Total 1927 11,798 127 1.08
Calendar year of follow-upa
≤2010 4936 19 0.38 1 <0.001 1 <0.001
2011 to 2013 3732 32 0.86 2.45 (1.21, 4.95) 0.013 2.34 (1.14, 4.79) 0.020
2014 to 2017 3131 76 2.43 7.76 (3.61, 16.66) <0.001 7.20 (3.27, 15.87) <0.001
Age at ART initiation (years)
≤30 552 3246 22 0.68 1 <0.001 1 <0.001
31 to 40 847 5164 52 1.01 1.45 (0.87, 2.43) 0.157 1.28 (0.75, 2.17) 0.363
41 to 50 381 2482 37 1.49 2.83 (1.62, 4.94) <0.001 2.46 (1.39, 4.36) 0.002
>50 147 906 16 1.77 4.37 (2.26, 8.46) <0.001 4.19 (2.12, 8.28) <0.001
Sex
Male 1426 8949 109 1.22 1 1
Female 501 2849 18 0.63 0.47 (0.28, 0.78) 0.004 0.47 (0.28, 0.80) 0.006
HIV mode of exposure
Heterosexual contact 1102 6720 70 1.04 1 0.391
MSM 554 3449 34 0.99 1.48 (0.80, 2.73) 0.207
IDU 105 477 12 2.51 1.67 (0.78, 3.57) 0.184
Other/Unknown 166 1152 11 0.96 1.33 (0.64, 2.76) 0.449
HIV viral load (copies/mL)a
≤1000 9326 94 1.01 1
>1000 1000 12 1.20 1.56 (0.77, 3.16) 0.216
Not done 1472 21 1.43
CD4 cell count (cells/lL)a
≤200 1732 23 1.33 1 0.615
201 to 350 2717 22 0.81 0.86 (0.44, 1.68) 0.651
351 to 500 3014 26 0.86 0.70 (0.35, 1.42) 0.322
>500 4300 56 1.3 0.81 (0.42, 1.57) 0.529
Not done 35 0 0
Initial cART regimen
NRTI + NNRTI 1497 8403 102 1.21 1 0.145
NRTI + PI 364 3066 22 0.72 0.55 (0.27, 1.11) 0.095
Other combination 66 329 3 0.91 1.54 (0.45, 5.23) 0.487
Stavudine in first-line ART?
No 1382 8682 80 0.92 1
Yes 545 3116 47 1.51 0.98 (0.61, 1.57) 0.924
Didanosine in first-line ART?
No 1879 11,391 120 1.05 1
Yes 48 406 7 1.72 1.85 (0.79, 4.37) 0.158
Hepatitis B co-infection
Negative 1599 9791 100 1.02 1
Positive 142 875 16 1.83 1.58 (0.91, 2.73) 0.102
Not tested 186 1132 11 0.97
Hepatitis C co-infection
Negative 1422 9131 96 1.05 1
Positive 204 1106 13 1.18 0.65 (0.33, 1.29) 0.219
Not tested 301 1561 18 1.15
Prior AIDS diagnosis
No 1367 8311 79 0.95 1
Yes 560 3486 48 1.38 1.35 (0.91, 1.99) 0.137
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The limitations of the study include the unavailability of
other indicators for central obesity such as abdominal fat and
waist-hip circumference ratio. We therefore were not able to
evaluate the effects of these indicators on the development of
DM in our analysis. Also, another limitation of this study is
that we did not include HIV-negative controls to compare the
incidence rates of DM between the groups. Due to the limita-
tions in DM testing data, such as FBG, we did not use a sec-
ond confirmatory testing for DM, which could possibly lead to
inaccurate estimation of our cohort’s DM incidence rate. As
our cohort recruit participants based on the likelihood of
remaining in care, the study population may not represent
patients typically seen at the clinical sites. Finally, our study
has limitations for inability to adjust all the unobserved con-
founding factors due to the observational nature of the
cohort.
4 | CONCLUSIONS
Our analysis shows DM in PLHIV is common in settings from
Asian countries. Traditional risk factors such as age, sex, high
blood pressure and BMI were found to be associated with
the development of DM in our cohort. Careful assessment
and routine screening for DM and other co-existing comorbid
conditions, especially among older and obese PLHIV, are
essential.
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(years) No of DM
Incidence rate
(/100PYS) HR (95% CI) p-value HR (95% CI) p-value
BMI (kg/m2)a
<18.5 884 7 0.79 1 0.009 1 0.025
18.5 to 25.0 6816 68 1.00 1.32 (0.59, 2.95) 0.491 1.06 (0.47, 2.38) 0.892
25.0 to 30.0 1666 19 1.14 1.89 (0.76, 4.70) 0.168 1.17 (0.46, 2.97) 0.736
>30.0 333 11 3.30 5.39 (1.94, 14.97) 0.001 4.30 (1.53, 12.09) 0.006
Not reported 2098 22 1.05
High blood pressurea
No 7562 73 0.97 1 1
Yes 1211 24 1.98 2.64 (1.52, 4.59) 0.001 2.05 (1.16, 3.63) 0.013
Not done 3025 30 0.99
Dyslipidaemiaa
No 4703 34 0.72 1
Yes 6371 81 1.27 1.49 (0.99, 2.24) 0.059
Not reported 724 12 1.66
Ever smoked
No 755 4674 41 0.88 1
Yes 663 4564 48 1.05 1.29 (0.83, 2.00) 0.263
Not reported 509 2560 38 1.48
Ever above moderate or low risk drinking
No 324 2256 20 0.89 1
Yes 107 694 10 1.44 1.15 (0.49, 2.73) 0.743
Not reported 1496 8847 97 1.10
p-vales in bold represent significant covariates in the final model. Global p-values are test for heterogeneity excluding missing values. Dyslipi-
daemia was defined as a single laboratory result of a fasting cholesterol >200 mg/dL or triglycerides >150 mg/dL. High blood pressure was
defined as having at least one measurement of systolic blood pressure >140 mmHg or diastolic blood pressure >90 mmHg. ART, antiretroviral
therapy; cART, combination antiretroviral therapy; IDU, injecting drug users; MSM, men who have sex with men; NNRTI, non-nucleoside reverse
transcriptase inhibitor; NRTI, nucleoside reverse transcriptase inhibitors; PI, protease inhibitor. aCalendar year of follow-up, CD4, VL, BMI, High
blood pressure, dyslipidaemia are time-updated variables.
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